# ResMed

Type: Company (RMD)

Source: GetYourBrief — https://getyourbrief.com/entity/resmed
Canonical HTML page: https://getyourbrief.com/entity/resmed

## Timeline

- **2026-11-18**: 2026 Annual Meeting of Stockholders — ResMed holds its annual meeting; Ron Taylor is not standing for reelection and will retire.
- **2026-11-15**: Carol Burt becomes Lead Director — Carol Burt's appointment as ResMed Lead Director takes effect.
- **2026-08-17**: ResMed announces leadership transition — ResMed issues a press release announcing Carol Burt will become Lead Director on November 15, 2026, and Ron Taylor will retire.
- **2013**: Carol Burt joins board; Taylor becomes Lead Director — Carol Burt joins ResMed's Board of Directors. In the same year, Ron Taylor assumes the role of Lead Director.
- **2005**: Ron Taylor joins ResMed board — Ron Taylor becomes a member of ResMed's Board of Directors, beginning a tenure that would last more than 21 years.

## Recent coverage (5 stories, network-wide)

### ResMed Names Carol Burt Lead Director as 21-Year Vet Ron Taylor Retires
2026-08-17 22:28:04 · Sector: health · Sentiment: Neutral · Impact: 5/10 · Sources: 2

ResMed is elevating governance and compliance expertise to its lead director role at a time when AI-enabled sleep and respiratory devices face rising regulatory and data privacy expectations. Carol Burt's appointment and Ron Taylor's retirement signal a deliberate board transition rather than disruption. Health systems, investors, and partners should watch committee assignments and product governance signals through the November 2026 annual meeting.
Full story: https://gethealthbrief.com/story/resmed-carol-burt-lead-director-health

### ASX 200 Eyes 12% Earnings Surge, First Growth in Years
2026-08-01 22:39:50 · Sector: finance · Sentiment: Neutral · Impact: 5/10 · Sources: 3

Australian companies are forecast to deliver 12% aggregate profit growth this earnings season, breaking a three-year decline. Key risks loom from energy costs, wage inflation, and rising bad debts, particularly for banks like CBA and Westpac.
Full story: https://getfinancebrief.com/story/asx-200-earnings-season-12-percent-growth

### ResMed Faces $270.64 Consensus Target Amid Analyst Divide on Sleep Device Demand
2026-07-10 14:15:23 · Sector: health · Sentiment: Neutral · Impact: 5/10 · Sources: 2

Analyst downgrades reflect growing fears that GLP-1 weight loss drugs could erode the sleep apnea device market, even as ResMed’s financials stay solid. The contrast between a $225 low target and $321 high target underscores sector uncertainty.
Full story: https://gethealthbrief.com/story/resmed-analyst-target-sleep-apnea-demand

### ResMed Targets Drop to $225 at Wells Fargo; Upside Remains at +23.2%
2026-07-10 14:15:12 · Sector: finance · Sentiment: Neutral · Impact: 5/10 · Sources: 2

Wells Fargo’s $225 target is the lowest among major banks, yet ResMed’s average analyst target of $270.64 implies a 23.2% upside. Markets weigh defensive balance sheet qualities against emerging therapeutic competition.
Full story: https://getfinancebrief.com/story/resmed-stock-analyst-target-cuts-wells-fargo

### ResMed’s $270.64 Consensus Hides a 30% Spread in Analyst Targets
2026-07-10 14:14:59 · Sector: bio · Sentiment: Neutral · Impact: 5/10 · Sources: 2

Biotech and life sciences investors face a paradox: ResMed’s stalwart medical device business is underpinned by low debt and high margins, yet analyst targets range from $225 to $321 as GLP-1 therapies threaten its patient base.
Full story: https://getbiobrief.com/story/resmed-analyst-divide-biotech-investment

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://getyourbrief.com/guides/methodology for the full editorial methodology.